The rationale against a "mandatory" extended hepatectomy in perihilar cholangiocarcinoma: meta-analysis.
메타분석
2/5 보강
TL;DR
This study shows no clear benefit of ES over RS for pCCA, suggesting non-inferiority of RS, and surgeons may consider a safer parenchymal sparing approach as long as radicality is not significantly compromised, especially for patients at higher risk of fatal PHLF.
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
50 patients with pCCA who underwent liver and extrahepatic bile duct resection with caudate lobe were included.
I · Intervention 중재 / 시술
liver and extrahepatic bile duct resection with caudate lobe were included
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Accounting for confounding, this study shows no clear benefit of ES over RS for pCCA, suggesting non-inferiority of RS. Surgeons may consider a safer parenchymal sparing approach as long as radicality is not significantly compromised, especially for patients at higher risk of fatal PHLF.
OpenAlex 토픽 ·
Cholangiocarcinoma and Gallbladder Cancer Studies
Gallbladder and Bile Duct Disorders
Hepatocellular Carcinoma Treatment and Prognosis
This study shows no clear benefit of ES over RS for pCCA, suggesting non-inferiority of RS, and surgeons may consider a safer parenchymal sparing approach as long as radicality is not significantly co
- 표본수 (n) 1090
- OR 0.91
- HR 1.2
- 연구 설계 systematic review
APA
A.M. Bonomi, S. Granieri, et al. (2026). The rationale against a "mandatory" extended hepatectomy in perihilar cholangiocarcinoma: meta-analysis.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 52(5), 111743. https://doi.org/10.1016/j.ejso.2026.111743
MLA
A.M. Bonomi, et al.. "The rationale against a "mandatory" extended hepatectomy in perihilar cholangiocarcinoma: meta-analysis.." European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 52, no. 5, 2026, pp. 111743.
PMID
41855741 ↗
Abstract 한글 요약
[INTRODUCTION] Traditional surgical teaching includes an extended hepatectomy for patients diagnosed with perihilar cholangiocarcinoma (pCCA). However, recent studies suggest it may not consistently lead to the best outcome.
[METHODS] A systematic review was conducted in PubMed, Embase, and Web of Science databases (inception - March 2025). Studies including at least 50 patients with pCCA who underwent liver and extrahepatic bile duct resection with caudate lobe were included. For each study, resections were reclassified as "Reference Surgery" (RS) or "Extended Surgery" (ES) according to the Kawaguchi-Gayet classification. Primary outcome was overall survival (OS). Secondary outcomes included: microscopic residual disease (R1), post-hepatectomy liver failure (PHLF), 90-day mortality rates. Hazard Ratios (HR), Odds Ratios (OR) with 95% Confidence Intervals (CI) represented outcome measures. Results after sensitivity analysis are reported.
[RESULTS] Overall, 4181 patients with resected pCCA from 17 retrospective studies were included. Proportion for Bismuth type was similar, except for type 3a (RS: 9.6%; ES: 41.6%). RS primarily comprised left hepatectomy (64.2%; n = 1090); ES mainly included right extended hepatectomy (35.7%; n = 1001). Overall, ES was negatively associated with OS (HR = 1.2; 95% CI = 1.07-1.34), did not improve R1 rate (OR = 0.91; 95% CI = 0.71-1.15), and was associated with a two-fold higher risk of PHLF and 90-day mortality.
[CONCLUSIONS] Accounting for confounding, this study shows no clear benefit of ES over RS for pCCA, suggesting non-inferiority of RS. Surgeons may consider a safer parenchymal sparing approach as long as radicality is not significantly compromised, especially for patients at higher risk of fatal PHLF.
[METHODS] A systematic review was conducted in PubMed, Embase, and Web of Science databases (inception - March 2025). Studies including at least 50 patients with pCCA who underwent liver and extrahepatic bile duct resection with caudate lobe were included. For each study, resections were reclassified as "Reference Surgery" (RS) or "Extended Surgery" (ES) according to the Kawaguchi-Gayet classification. Primary outcome was overall survival (OS). Secondary outcomes included: microscopic residual disease (R1), post-hepatectomy liver failure (PHLF), 90-day mortality rates. Hazard Ratios (HR), Odds Ratios (OR) with 95% Confidence Intervals (CI) represented outcome measures. Results after sensitivity analysis are reported.
[RESULTS] Overall, 4181 patients with resected pCCA from 17 retrospective studies were included. Proportion for Bismuth type was similar, except for type 3a (RS: 9.6%; ES: 41.6%). RS primarily comprised left hepatectomy (64.2%; n = 1090); ES mainly included right extended hepatectomy (35.7%; n = 1001). Overall, ES was negatively associated with OS (HR = 1.2; 95% CI = 1.07-1.34), did not improve R1 rate (OR = 0.91; 95% CI = 0.71-1.15), and was associated with a two-fold higher risk of PHLF and 90-day mortality.
[CONCLUSIONS] Accounting for confounding, this study shows no clear benefit of ES over RS for pCCA, suggesting non-inferiority of RS. Surgeons may consider a safer parenchymal sparing approach as long as radicality is not significantly compromised, especially for patients at higher risk of fatal PHLF.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.